Wright Investors Service Inc. Boosts Stake in Charles River Laboratories International, Inc. (CRL)

Wright Investors Service Inc. grew its position in Charles River Laboratories International, Inc. (NYSE:CRL) by 9.0% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 7,191 shares of the medical research company’s stock after purchasing an additional 596 shares during the quarter. Wright Investors Service Inc.’s holdings in Charles River Laboratories International were worth $777,000 as of its most recent SEC filing.

Several other institutional investors have also recently bought and sold shares of the company. Alps Advisors Inc. grew its position in shares of Charles River Laboratories International by 0.3% in the second quarter. Alps Advisors Inc. now owns 5,350 shares of the medical research company’s stock valued at $541,000 after purchasing an additional 14 shares during the last quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS grew its position in shares of Charles River Laboratories International by 0.5% in the second quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 6,953 shares of the medical research company’s stock valued at $703,000 after purchasing an additional 33 shares during the last quarter. Bbva Compass Bancshares Inc. grew its position in shares of Charles River Laboratories International by 0.8% in the second quarter. Bbva Compass Bancshares Inc. now owns 6,004 shares of the medical research company’s stock valued at $607,000 after purchasing an additional 50 shares during the last quarter. World Asset Management Inc grew its position in shares of Charles River Laboratories International by 2.2% in the second quarter. World Asset Management Inc now owns 2,762 shares of the medical research company’s stock valued at $279,000 after purchasing an additional 59 shares during the last quarter. Finally, M&T Bank Corp grew its position in shares of Charles River Laboratories International by 1.8% in the second quarter. M&T Bank Corp now owns 4,358 shares of the medical research company’s stock valued at $441,000 after purchasing an additional 76 shares during the last quarter. 97.63% of the stock is currently owned by institutional investors.

Shares of Charles River Laboratories International, Inc. (NYSE CRL) traded up 1.14% during midday trading on Wednesday, reaching $117.61. The company had a trading volume of 164,591 shares. Charles River Laboratories International, Inc. has a one year low of $67.20 and a one year high of $118.66. The firm has a market capitalization of $5.60 billion, a P/E ratio of 30.99 and a beta of 0.96. The company has a 50 day moving average price of $110.71 and a 200-day moving average price of $100.54.

Charles River Laboratories International (NYSE:CRL) last released its quarterly earnings data on Wednesday, August 9th. The medical research company reported $1.29 earnings per share for the quarter, beating analysts’ consensus estimates of $1.22 by $0.07. Charles River Laboratories International had a net margin of 10.13% and a return on equity of 27.02%. The business had revenue of $469.13 million during the quarter, compared to analyst estimates of $458.25 million. During the same period in the previous year, the business earned $1.20 EPS. Charles River Laboratories International’s revenue was up 8.1% compared to the same quarter last year. On average, analysts anticipate that Charles River Laboratories International, Inc. will post $5.10 EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This piece was originally posted by Sports Perspectives and is the property of of Sports Perspectives. If you are viewing this piece on another domain, it was illegally copied and republished in violation of United States & international trademark & copyright legislation. The correct version of this piece can be accessed at https://sportsperspectives.com/2017/11/01/wright-investors-service-inc-boosts-stake-in-charles-river-laboratories-international-inc-crl.html.

In other news, insider Davide Molho sold 5,982 shares of the business’s stock in a transaction on Tuesday, September 5th. The shares were sold at an average price of $107.55, for a total transaction of $643,364.10. Following the completion of the transaction, the insider now directly owns 22,714 shares in the company, valued at approximately $2,442,890.70. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider William D. Barbo sold 4,000 shares of the business’s stock in a transaction on Thursday, August 17th. The shares were sold at an average price of $99.91, for a total transaction of $399,640.00. Following the transaction, the insider now owns 20,424 shares of the company’s stock, valued at $2,040,561.84. The disclosure for this sale can be found here. Insiders sold a total of 18,699 shares of company stock valued at $1,892,393 over the last quarter. 2.20% of the stock is owned by company insiders.

Several research firms have recently commented on CRL. Zacks Investment Research raised Charles River Laboratories International from a “hold” rating to a “buy” rating and set a $129.00 target price on the stock in a research report on Tuesday, October 24th. Jefferies Group LLC upped their target price on Charles River Laboratories International from $120.00 to $130.00 and gave the company a “buy” rating in a research report on Monday, October 9th. BidaskClub raised Charles River Laboratories International from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, August 22nd. Barclays PLC reaffirmed a “hold” rating and issued a $102.00 target price on shares of Charles River Laboratories International in a research report on Wednesday, July 19th. Finally, Credit Suisse Group reaffirmed a “neutral” rating and issued a $112.00 target price (up previously from $95.00) on shares of Charles River Laboratories International in a research report on Monday, October 16th. Five research analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company. Charles River Laboratories International has a consensus rating of “Buy” and an average target price of $103.77.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc is an early-stage contract research company. The Company is engaged in laboratory animal medicine and science (research model technologies) and develop a portfolio of discovery and safety assessment services, both good laboratory practice (GLP) and non-GLP, which supports its clients from target identification through non-clinical development.

Institutional Ownership by Quarter for Charles River Laboratories International (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply